{"classes":[{"categories":[{"measurements":[{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG004","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG005","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG006","spread":"NA","value":"NA"},{"comment":"The data is not evaluable as the samples were BLLQ.","groupId":"OG007","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"36"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"18"}],"units":"Participants"}],"title":"Cycle 1 Day 2: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.4","value":"33.2"},{"groupId":"OG001","spread":"25.4","value":"36.6"},{"groupId":"OG002","spread":"29.1","value":"37.5"},{"groupId":"OG003","spread":"20.3","value":"34.3"},{"groupId":"OG004","spread":"27.7","value":"35.4"},{"groupId":"OG005","spread":"26.2","value":"34.6"},{"groupId":"OG006","spread":"22.8","value":"32.4"},{"groupId":"OG007","spread":"20.3","value":"38.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"19"}],"units":"Participants"}],"title":"Cycle 1 Day 2: 30 min Post Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4393.4","value":"3.43"},{"groupId":"OG001","spread":"43.7","value":"9.01"},{"groupId":"OG002","spread":"39.3","value":"10.2"},{"groupId":"OG003","spread":"31.9","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1784.3","value":"1.83"},{"groupId":"OG001","spread":"35.3","value":"4.26"},{"groupId":"OG002","spread":"40.6","value":"4.61"},{"groupId":"OG003","spread":"28.4","value":"5.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"941.2","value":"0.696"},{"groupId":"OG001","spread":"54.2","value":"2.31"},{"groupId":"OG002","spread":"76.1","value":"2.20"},{"groupId":"OG003","spread":"27.4","value":"3.70"},{"groupId":"OG004","spread":"203.1","value":"1.23"},{"groupId":"OG005","spread":"137.6","value":"2.48"},{"groupId":"OG006","spread":"100.6","value":"2.20"},{"groupId":"OG007","spread":"41.8","value":"2.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"16"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.9","value":"35.8"},{"groupId":"OG001","spread":"28.3","value":"39.5"},{"groupId":"OG002","spread":"31.1","value":"43.4"},{"groupId":"OG003","spread":"22.9","value":"42.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Cycle 2 Day 1: 30 min Post Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.5","value":"3.44"},{"groupId":"OG001","spread":"59.0","value":"5.03"},{"groupId":"OG002","spread":"62.2","value":"4.61"},{"groupId":"OG003","spread":"18.3","value":"6.26"},{"groupId":"OG004","spread":"97.8","value":"3.61"},{"groupId":"OG005","spread":"39.9","value":"5.72"},{"groupId":"OG006","spread":"20.8","value":"4.82"},{"groupId":"OG007","spread":"29.3","value":"5.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.2","value":"40.2"},{"groupId":"OG001","spread":"11.0","value":"44.6"},{"groupId":"OG002","spread":"25.8","value":"43.0"},{"groupId":"OG003","spread":"24.2","value":"47.1"},{"groupId":"OG004","spread":"24.3","value":"44.8"},{"groupId":"OG005","spread":"20.6","value":"40.6"},{"groupId":"OG006","spread":"21.3","value":"55.0"},{"groupId":"OG007","spread":"11.6","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"Cycle 4 Day 1: 30 min Post Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.9","value":"0.164"},{"groupId":"OG001","spread":"193.4","value":"0.771"},{"groupId":"OG002","spread":"82.8","value":"0.910"},{"groupId":"OG003","spread":"27.1","value":"0.394"},{"groupId":"OG004","spread":"209.9","value":"0.265"},{"groupId":"OG005","spread":"266.2","value":"0.316"},{"groupId":"OG006","spread":"174.2","value":"0.489"},{"groupId":"OG007","spread":"126.7","value":"0.543"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"Follow up on Month 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"0.0250"},{"groupId":"OG001","spread":"230.0","value":"0.0788"},{"groupId":"OG002","spread":"96.6","value":"0.219"},{"groupId":"OG003","spread":"18.5","value":"0.104"},{"groupId":"OG004","spread":"145.7","value":"0.0539"},{"groupId":"OG005","spread":"195.7","value":"0.0564"},{"groupId":"OG006","spread":"123.5","value":"0.0920"},{"groupId":"OG007","spread":"206.6","value":"0.150"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"title":"Follow up on Month 6, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"0.0250"},{"groupId":"OG001","spread":"0.0","value":"0.0250"},{"groupId":"OG002","spread":"35.9","value":"0.0298"},{"groupId":"OG003","spread":"0.0","value":"0.0250"},{"groupId":"OG004","spread":"0.0","value":"0.0250"},{"groupId":"OG005","spread":"60.6","value":"0.0301"},{"groupId":"OG006","spread":"0.0","value":"0.0250"},{"groupId":"OG007","spread":"0.0","value":"0.0250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"Follow up on Month 12, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"0.0250"},{"groupId":"OG001","spread":"0.0","value":"0.0250"},{"groupId":"OG002","spread":"0.0","value":"0.0250"},{"groupId":"OG003","spread":"0.0","value":"0.0250"},{"groupId":"OG004","spread":"0.0","value":"0.0250"},{"groupId":"OG006","spread":"0.0","value":"0.0250"},{"groupId":"OG007","spread":"0.0","value":"0.0250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"Follow up on Month 18, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"0.0250"},{"groupId":"OG001","spread":"0.0","value":"0.0250"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG002","spread":"NA","value":"0.0250"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated..","groupId":"OG003","spread":"NA","value":"0.0250"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG007","spread":"NA","value":"0.0250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"Follow up on Month 24, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"0.0250"},{"groupId":"OG001","spread":"0.0","value":"0.0250"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG003","spread":"NA","value":"0.0250"},{"groupId":"OG005","spread":"5419.8","value":"1.65"},{"groupId":"OG006","spread":"30267.8","value":"1.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Unscheduled Visit"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG004","spread":"NA","value":"0.279"},{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG005","spread":"NA","value":"0.0250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Unscheduled Visit: Pre-dose"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG005","spread":"NA","value":"42.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Unscheduled Visit: 30 min Post Dose"},{"categories":[{"measurements":[{"comment":"Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.","groupId":"OG002","spread":"NA","value":"5.34"},{"groupId":"OG004","spread":"180.5","value":"3.34"},{"groupId":"OG005","spread":"69.4","value":"4.33"},{"groupId":"OG006","spread":"57.2","value":"4.57"},{"groupId":"OG007","spread":"79.3","value":"3.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"Study Treatment Completion Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"36"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"19"}],"units":"Participants"}],"description":"PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG001","title":"Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL"},{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG002","title":"Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG003","title":"Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL"},{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG004","title":"Arm A (Phase II Randomization): Pola+BR in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG005","title":"Arm C (Phase II Randomization): Pola+BR in DLBCL"},{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG006","title":"Arm E (Phase II Expansion): Pola+BG in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG007","title":"Arm F (Phase II Expansion): Pola+BG in DLBCL"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population included all the ITT participants Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 2: pre-dose & 30 min post dose; Cycle 1 Days 8 & 15; Cycle 2 and 4 Day 1 and unscheduled visits: pre-dose & 30 min post dose; Follow up at Day 1: Months 3, 6, 12, 18 & 24; study treatment completion visit (up to approx. 84 months)","title":"Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab","type":"SECONDARY","unitOfMeasure":"grams per milliliters (g/mL)"}